KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Depreciation & Amortization (CF) (2016 - 2026)

Amgen has reported Depreciation & Amortization (CF) over the past 18 years, most recently at $1.1 billion for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) fell 19.54% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $4.9 billion, down 12.26%, while the annual FY2025 figure was $5.2 billion, 7.6% down from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 was $1.1 billion at Amgen, down from $1.1 billion in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.4 billion in Q2 2024 and troughed at $828.0 million in Q2 2022.
  • A 5-year average of $1.1 billion and a median of $1.1 billion in 2025 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 56.25% in 2024 and later dropped 19.54% in 2026.
  • Year by year, Depreciation & Amortization (CF) stood at $911.0 million in 2022, then soared by 51.48% to $1.4 billion in 2023, then increased by 1.23% to $1.4 billion in 2024, then dropped by 18.97% to $1.1 billion in 2025, then dropped by 1.41% to $1.1 billion in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for AMGN at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.